Research ExplorerPublicationsDonor selection for a second allogeneic stem cell transplant...

Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT

Standard

Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT. / Shimoni, Avichai; Labopin, Myriam; Finke, Jürgen; Ciceri, Fabio; Deconinck, Eric; Kröger, Nicolaus; Gramatzki, Martin; Stelljes, Matthias; Blaise, Didier; Stoelzel, Friedrich; Chevallier, Patrice; Holler, Ernst; Fegueux, Nathalie; Mohty, Mohamad; Nagler, Arnon.

In: BLOOD CANCER J, Vol. 9, No. 12, 18.11.2019, p. 88.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Shimoni, A, Labopin, M, Finke, J, Ciceri, F, Deconinck, E, Kröger, N, Gramatzki, M, Stelljes, M, Blaise, D, Stoelzel, F, Chevallier, P, Holler, E, Fegueux, N, Mohty, M & Nagler, A 2019, 'Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT', BLOOD CANCER J, vol. 9, no. 12, pp. 88. https://doi.org/10.1038/s41408-019-0251-3

APA

Shimoni, A., Labopin, M., Finke, J., Ciceri, F., Deconinck, E., Kröger, N., Gramatzki, M., Stelljes, M., Blaise, D., Stoelzel, F., Chevallier, P., Holler, E., Fegueux, N., Mohty, M., & Nagler, A. (2019). Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT. BLOOD CANCER J, 9(12), 88. https://doi.org/10.1038/s41408-019-0251-3

Vancouver

Shimoni A, Labopin M, Finke J, Ciceri F, Deconinck E, Kröger N et al. Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT. BLOOD CANCER J. 2019 Nov 18;9(12):88. https://doi.org/10.1038/s41408-019-0251-3

Bibtex

@article{c9edb5877289465ba6c32134c6f074d1,
title = "Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT",
abstract = "Second allogeneic stem-cell transplantation (SCT2) is a therapeutic option for patients with AML relapsing after a first transplant. Prior studies have shown similar results after SCT2 from the same or different donor; however, there are limited data on second non-T-depleted haplo-identical transplant in this setting. We retrospectively analyzed SCT2 outcomes in 556 patients, median age 46 years, relapsing after first transplant given in CR1. Patients were divided into three groups based on SCT2 donor (donor2): same donor (n = 163, sib/sib-112, UD/UD-51), different matched donor (n = 305, sib/different sib-44, sib/UD-93, UD/different UD-168), or haplo-donor (n = 88, sib/haplo-45, UD/haplo-43). Two-year leukemia-free survival (LFS) rate after SCT2 was 23.5%, 23.7%, and 21.8%, respectively (P = 0.30). Multivariate analysis showed no effect of donor2 type on relapse: hazard ratio (HR) 0.89 (P = 0.57) and 1.11 (P = 0.68) for different donor and haplo-donor compared to same donor, respectively. However, donor2 did predict for non-relapse mortality (NRM) after SCT2: HR 1.21 (P = 0.50) and 2.08 (P = 0.03), respectively, and for LFS: HR 1.00 (P = 0.97) and 1.43 (P = 0.07), respectively. In conclusion, SCT2 with the same or different matched donor is associated with similar outcomes in patients with relapsed AML. Non-T-depleted haplo-identical transplant may be associated with higher NRM, similar relapse rate and with no better results in this setting.",
author = "Avichai Shimoni and Myriam Labopin and J{\"u}rgen Finke and Fabio Ciceri and Eric Deconinck and Nicolaus Kr{\"o}ger and Martin Gramatzki and Matthias Stelljes and Didier Blaise and Friedrich Stoelzel and Patrice Chevallier and Ernst Holler and Nathalie Fegueux and Mohamad Mohty and Arnon Nagler",
year = "2019",
month = nov,
day = "18",
doi = "10.1038/s41408-019-0251-3",
language = "English",
volume = "9",
pages = "88",
journal = "BLOOD CANCER J",
issn = "2044-5385",
publisher = "NATURE PUBLISHING GROUP",
number = "12",

}

RIS

TY - JOUR

T1 - Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT

AU - Shimoni, Avichai

AU - Labopin, Myriam

AU - Finke, Jürgen

AU - Ciceri, Fabio

AU - Deconinck, Eric

AU - Kröger, Nicolaus

AU - Gramatzki, Martin

AU - Stelljes, Matthias

AU - Blaise, Didier

AU - Stoelzel, Friedrich

AU - Chevallier, Patrice

AU - Holler, Ernst

AU - Fegueux, Nathalie

AU - Mohty, Mohamad

AU - Nagler, Arnon

PY - 2019/11/18

Y1 - 2019/11/18

N2 - Second allogeneic stem-cell transplantation (SCT2) is a therapeutic option for patients with AML relapsing after a first transplant. Prior studies have shown similar results after SCT2 from the same or different donor; however, there are limited data on second non-T-depleted haplo-identical transplant in this setting. We retrospectively analyzed SCT2 outcomes in 556 patients, median age 46 years, relapsing after first transplant given in CR1. Patients were divided into three groups based on SCT2 donor (donor2): same donor (n = 163, sib/sib-112, UD/UD-51), different matched donor (n = 305, sib/different sib-44, sib/UD-93, UD/different UD-168), or haplo-donor (n = 88, sib/haplo-45, UD/haplo-43). Two-year leukemia-free survival (LFS) rate after SCT2 was 23.5%, 23.7%, and 21.8%, respectively (P = 0.30). Multivariate analysis showed no effect of donor2 type on relapse: hazard ratio (HR) 0.89 (P = 0.57) and 1.11 (P = 0.68) for different donor and haplo-donor compared to same donor, respectively. However, donor2 did predict for non-relapse mortality (NRM) after SCT2: HR 1.21 (P = 0.50) and 2.08 (P = 0.03), respectively, and for LFS: HR 1.00 (P = 0.97) and 1.43 (P = 0.07), respectively. In conclusion, SCT2 with the same or different matched donor is associated with similar outcomes in patients with relapsed AML. Non-T-depleted haplo-identical transplant may be associated with higher NRM, similar relapse rate and with no better results in this setting.

AB - Second allogeneic stem-cell transplantation (SCT2) is a therapeutic option for patients with AML relapsing after a first transplant. Prior studies have shown similar results after SCT2 from the same or different donor; however, there are limited data on second non-T-depleted haplo-identical transplant in this setting. We retrospectively analyzed SCT2 outcomes in 556 patients, median age 46 years, relapsing after first transplant given in CR1. Patients were divided into three groups based on SCT2 donor (donor2): same donor (n = 163, sib/sib-112, UD/UD-51), different matched donor (n = 305, sib/different sib-44, sib/UD-93, UD/different UD-168), or haplo-donor (n = 88, sib/haplo-45, UD/haplo-43). Two-year leukemia-free survival (LFS) rate after SCT2 was 23.5%, 23.7%, and 21.8%, respectively (P = 0.30). Multivariate analysis showed no effect of donor2 type on relapse: hazard ratio (HR) 0.89 (P = 0.57) and 1.11 (P = 0.68) for different donor and haplo-donor compared to same donor, respectively. However, donor2 did predict for non-relapse mortality (NRM) after SCT2: HR 1.21 (P = 0.50) and 2.08 (P = 0.03), respectively, and for LFS: HR 1.00 (P = 0.97) and 1.43 (P = 0.07), respectively. In conclusion, SCT2 with the same or different matched donor is associated with similar outcomes in patients with relapsed AML. Non-T-depleted haplo-identical transplant may be associated with higher NRM, similar relapse rate and with no better results in this setting.

U2 - 10.1038/s41408-019-0251-3

DO - 10.1038/s41408-019-0251-3

M3 - SCORING: Journal article

C2 - 31740656

VL - 9

SP - 88

JO - BLOOD CANCER J

JF - BLOOD CANCER J

SN - 2044-5385

IS - 12

ER -